Drug intelligence / Profile preview

KL0011034

Development stage: Phase 1
Lead developer: Hunan Kelun Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

KL0011034 is an investigational intravenous anesthetic agent being developed by Hunan Kelun Pharmaceutical Co., Ltd. It is currently in Phase 1 clinical development for the induction of general anesthesia. In clinical studies, it is being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers, often using etomidate as a positive control. As a sedative-hypnotic intended for anesthesia, its mechanism of action likely involves the modulation of the GABA-A receptor complex, similar to other agents in its class like etomidate or propofol, to induce a rapid state of unconsciousness.

Targets

GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on KL0011034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL0011034.

Explore the full profile